Skip to main content

Table 2 Realized and Unrealized Savings for the biosimilars Basaglar®, Grastofil®, and Inflectra® Relative to Captured Market Share by Province

From: Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis

Combined Total

BC

AB

SK

MB

ON

QC

NB

NS

PEI/NL

Total

Relative Market Share

25%

$27,928,392

$35,351,847

$7,050,947

$10,825,836

$92,858,064

$69,340,492

$10,224,942

$12,572,878

$7,232,388

$273,720,060

50%

$55,856,785

$70,703,694

$14,101,894

$21,651,672

$185,716,128

$138,680,983

$20,449,885

$25,145,756

$14,464,775

$547,440,121

75%

$83,785,177

$106,055,541

$21,152,840

$32,477,508

$278,574,191

$208,021,475

$30,674,827

$37,718,634

$21,697,163

$821,160,181

100%

$111,713,570

$141,407,387

$28,203,787

$43,303,343

$371,432,255

$277,361,966

$40,899,770

$50,291,511

$28,929,550

$1,094,880,242

Realized Savings

($)

$7,174,406

$3,332,450

$1,174,422

$2,232,171

$21,988,985

$8,019,828

$912,786

$615,111

$709,443

$46,168,848

(%)

6.42%

2.36%

4.16%

5.15%

5.92%

2.89%

2.23%

1.22%

2.45%

4.22%

Unrealized Savings

($)

$104,539,164

$138,074,937

$27,029,365

$41,071,172

$349,443,270

$269,342,139

$39,986,984

$49,676,400

$28,220,107

$1,048,711,394

(%)

93.58%

97.64%

95.84%

94.85%

94.08%

97.11%

97.77%

98.78%

97.55%

95.78%

  1. All dollar figures are in Canadian dollars
  2. BC British Columbia, AB Alberta, SK Saskatchewan, MB Manitoba, ON Ontario, QC Quebec, NB New Brunswick, NS Nova Scotia, PEI/NL Prince Edward Island / Newfoundland
  3. Realized savings is calculated as the difference in price between the originator and biosimilar in each particular province, multiplied by the number of biosimilar units sold
  4. Unrealized savings is calculated as the difference in price between the originator and biosimilar in each particular province, multiplied by the number of originator units sold